PARP inhibitors such as olaparib effectively target the dysfunctional BRCA1/2 pathways but can also benefit patients with other HRD mutations or epigenetic modulation such as ATM, BARD1, MRE11, RAD51, and PALB2 [9,62], highlighting the complexity of tailoring therapies to the genetic landscape of ovarian cancer. The gene discussed is BRCA1; the disease is ovarian carcinoma.